Schizophrenia Treatment Adherence Investigation (STAI)

Not Applicable

Completed

• Conditions: Schizophrenia or Schizoaffective disorder; Mental Health - Schizophrenia

• Registration Number: ACTRN12607000250437
• Lead Sponsor: Janssen-Cilag Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05-10
• Study Completion: 2009-09-01
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 550

Inclusion Criteria

Clinical diagnosis of Schizophrenia or Schizoaffective Disorder according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition). Currently treated in an outpatient clinic. Over 18 years and able to provide informed consent.

Exclusion Criteria

There is no exclusion criteria for this treatment review.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome of this treatment review is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. [ Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.]

Secondary Outcome Measures

Name	Time	Method
1. Reporting on the proportion of patients with schizophrenia who may be inappropriately clinically and/or medically treated in the context of their medication adherence risk status. <br>[ Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.];2. Quantifying any antipsychotic medication modification and relating this to the treatment review factors captured at baseline. <br>[ Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.];3. Relating the adherence risk status to the medications used and the actual acute exacerbation rate.[ Participant medication adherence will be assessed at baseline, 6 month follow up and 12 month follow up. Follow up will consist of a review of the participants medical records only.]